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Abstract
Background: After progression to a standard first-line platinum and gemcitabine combination (GP), there is no
established second-line therapy for patients with advanced biliary tract cancers (aBTC). Indeed, literature data
suggest limited activity of most second-line agents evaluated so far.
Methods: We collected a large retrospective series of aBTC patients treated with second-line chemotherapy after
progression to a first-line GP regimen at different Italian institutions. We then pooled the data with those reported
in previous studies, which were identified with a Medline search and the on-line abstract datasets of major
international oncology meetings.
Results: A total of 174 patients were included in the multicenter survey: response rate (RR) with second-line
chemotherapy was low (3.4 %), with median PFS and OS of 3.0 months and 6.6 months, respectively. At
multivariate analysis, preserved performance status, low CA19.9 levels and absence of distant metastases were
favorable prognostic factors. Data from other five presented or published series were identified, for a total of 499
patients included in the pooled analysis. The results confirmed marginal activity of second-line chemotherapy (RR:
10.2 %), with limited efficacy in unselected patient populations (median PFS: 3.1 months; median OS: 6.3 months).
Conclusions: The current analysis highlights the limited value of second-line chemotherapy after a first-line GP
combination in aBTC. While waiting for effective biologic agents in this setting, ongoing randomized trials will
identify the optimal second-line chemotherapy regimen and validate prognostic factors for individual patient
management.
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Background
Biliary tract cancers (BTC) represent an uncommon
group of malignancies that includes intra- and extra-
hepatic cholangiocarcinoma, tumors of the gallbladder
and tumors of the ampulla of Vater [1]. The only poten-
tially curative approach to BTC is represented by radical
resection in early stage: however, surgery is burdened by
a high rate of recurrence [1]. In the majority of cases,
disease occurs in an advanced stage and prognosis re-
mains poor, with median overall survival (OS) times
rarely exceeding the range 10–12 months [2]. In this set-
ting, chemotherapy constitutes the mainstay of treat-
ment strategy. In the past decades some phase III
studies demonstrated that chemotherapy improves both
OS and quality of life in advanced BTC (aBTC), although
the magnitude of benefit from palliative therapy is lim-
ited [3–5].
More recently, two randomized phase II and III stud-
ies have demonstrated significant survival advantage for
the combination of gemcitabine and cisplatin over gem-
citabine alone for patients with aBTC [6, 7]: gemcitabine
plus cisplatin thus represents the current standard of
care as first-line therapy. Even in the absence of phase
III data formally supporting the equivalence of different
platinum salts in aBTC, oxaliplatin is widely considered
a reasonable alternative to cisplatin: therefore, the com-
bination of gemcitabine and oxaliplatin is often used in
clinical practice as well as clinical trials as chemotherapy
backbone for the evaluation of targeted agents [2]. After
progression on a gemcitabine plus a platinum derivative
(GP), the value of second-line chemotherapy remains an
unresolved issue. Several studies suggested that second-
line treatment could be helpful for selected patients with
good performance status, but no consensus has ever de-
fined the most suitable regimen to use and the right pa-
tient to treat [8].
Lamarca et al. has recently conducted a systematic re-
view of the literature to evaluate the level of evidence
behind the use of second-line chemotherapy in aBTC
patients [9]. Data from twenty-five studies (for a total of
761 patients) were collected, with a mean OS of
7.2 months, a mean progression-free survival (PFS) of
3.2 months and a response rate (RR) of 7.7 %. According
to these results, the authors concluded that there is in-
sufficient evidence to recommend a second-line chemo-
therapy in the whole population of patients with aBTC,
although a cohort of selected cases might benefit from
treatment. We have recently collected the largest series
of aBTC patients treated with second-line chemotherapy
[10, 11]: the results of our retrospective analysis are con-
sistent with those reported by Lamarca and colleagues.
With regards to first-line therapy, both reports from
Lamarca and our group presented high heterogeneity in
terms of first-line treatments [9, 10]. Moreover, in some
cases, second-line treatment was represented by targeted
agents, which have not demonstrated definitive efficacy
in this disease [8, 11]. We may conclude that in het-
erogeneous populations, second-line treatment has a
fairly limited role, but a rigorous estimate of second-
line treatment benefit after first-line GP is currently
lacking [9, 10].
In this report we aimed to define the results of
second-line chemotherapy after a first-line GP combin-
ation in a large, retrospective aBTC patients’ cohort.
Moreover, we performed a systematic review of the lit-
erature and pooled our data with those of other similar
studies, in order to better assess the role of second-line
treatment in patients with aBTC after the failure of first-
line GP chemotherapy.
Methods
Patients selection (retrospective analysis)
For the multicenter survey, we retrospectively identified
patients with aBTC treated with second-line chemother-
apy at 10 Italian Institutions between 2004 and 2013.
Details about the selection criteria applied were reported
elsewhere [10]. In summary, eligible patients had to have
a cytologically and/or histologically confirmed diagnosis
of non-resectable, recurrent or metastatic biliary tract
adenocarcinoma (intrahepatic or extrahepatic cholan-
giocarcinoma, gallbladder and ampullary carcinoma)
and a radiologically confirmed progression after first-
line chemotherapy with a GP doublet (gemcitabine
plus cisplatin or oxaliplatin).
Study selection (pooled analysis)
In order to better evaluate the role of second-line
chemotherapy in aBTC, we combined the patients iden-
tified in the multicenter survey with other published
series of patients with similar inclusion criteria. We
therefore searched for eligible studies using the Medline
database. Abstracts of the proceedings of the Annual
Meeting of the American Society of Clinical Oncology
(ASCO), the biannual European Society of Medical On-
cology Congress since 2002 (ESMO) and the annual
World Gastrointestinal Congress since 2006 were also
searched manually. We applied the research criteria yet
described in the systematic review published by Lamarca
et al. [9].
Statistical analysis
Measure of second-line chemotherapy activity and effi-
cacy for the retrospective cohort were the following: i)
RR: evaluated by Response Evaluation Criteria in Solid
Tumors (RECIST) v. 1.0; ii) PFS: measured from the
date of the first cycle of second-line chemotherapy to
the date of disease progression or death, whichever oc-
curred first; iii) OS: measured from the date of the first
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cycle of second-line chemotherapy to the date of death
for any cause. PFS and OS were estimated using the
Kaplan-Meier product-limit method. The log-rank test
was used to assess differences between subgroups.
The hazard ratio (HR) and the confidence intervals
(CIs) were estimated for each variable by means of the
Cox univariate model. A multivariate Cox regression
model was also developed with stepwise regression (for-
ward selection) by selecting those variables that were
significant on univariate analysis. Entry and removal
limits were p < 0.10 and p > 0.15, respectively.
To reduce the selection biases related to a non-
randomized cohort, propensity score for the likelihood
of receiving combination regimens or single-agent
chemotherapy was calculated from variables unmatched
[12]. By using a 1:1 nearest neighbor matching algorithm
that pairs patients with the closest propensity scores
within a defined limit (calipers of width equal to 0.2),
the propensity score yielded 2 well-matched cohorts of
98 patients (logistic regression estimation algorithm).
Multivariable Cox proportional hazard models were fur-
ther performed in the final sample.
A weighted combined analysis of the data of our sur-
vey and the published data of the identified series was
performed: all the available end points (RR, PFS and OS)
were investigated. Median values and corresponding
95 % CIs were calculated for both PFS and OS and were
weighted according to the number of patients enrolled
in the analyzed studies. The ratio of the number of
responding patients and the number of enrolled patients
in the selected studies was used to estimate RR. Case re-
ports were excluded from the analysis.
Statistical analyses were carried out using the statis-
tical software package Comprehensive Meta-analysis
vers. 3.3 (Biostat, Inc, Englewood, NJ, USA) and SPSS
software vers. 21.0 (IBM Corporation, Armonk, NY,
USA).
Results
Characteristics of the patients included in the multicenter
survey
A total of 174 patients have been included in the retro-
spective multicenter survey: the clinical characteristics of
this cohort are reported in Table 1.
Five other trials (one phase II study [13] and four
retrospective series [14–17]) reporting the results of
second-line chemotherapy in aBTC patients treated with
a first-line GP regimen have been identified by the re-
search strategy.
Results of the multicenter survey
The second-line regimens used in the 174 patients are
listed in Table 2. As regards activity, RR to second-line
chemotherapy was low (3.4 %; 95 % CI 0.7 %-6.1 %),
even though disease control was achieved in 50 patients
(28.7 %). After a median follow up of 23.0 months, 154
patients have progressed and 133 have died. Median PFS
was 3.0 months (95 % CI: 2.7-3.4) and median OS was
6.6 months (95 % CI: 5.1-8.1). Seventy-four patients
(42.5 %) received a third-line chemotherapy after disease
progression (Table 1). No major differences in response
or survival have been identified according to response
and PFS to first-line therapy.
Table 1 Retrospective cohort: patient characteristics
Characteristics n. (%)
Total n. of patients 174 (100)
Sex
Male 80 (46)
Female 94 (54)
Median age (range) 62 years (28–79)
ECOG Performance Status
0 106 (61)
1 52 (30)
2 16 (9)
Site of primary tumor
Intrahepatic 86 (49)
Extrahepatic 37 (21)
Gallbladder 34 (20)
Ampullary 17 (10)
CA19.9 before second-line CT
<Median value (157 U/ml) 71 (41)
≥Median value (157 U/ml) 83 (48)
Data missing 20 (11)
Previous response to first-line CT
Partial response 37 (21.3)
Stable disease 70 (40.3)
Progressive disease 67 (38.4)
Median PFS to first-line CT 5.8 months
Third-line CT received 74 (43)
Platinum plus or minus
gemcitabine or fluoropyrimidine
24 (14)
Irinotecan plus or minus
5-fluorouracil or capecitabine
17 (10)
Monotherapy with 5-fluorouracil
or capecitabine
10 (6)
Monotherapy with paclitaxel or docetaxel 7 (4)
Monotherapy with epirubicin 5 (3)
Other regimens 11 (6)
Abbreviations: n number, CT chemotherapy, PFS progression-free survival;
platinum: cisplatin, oxaliplatin or carboplatin; other regimens: different
combinations with fluoropyrimidines and other agents (taxanes,
anthracyclines, gemcitabine)
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In order to identify an optimal chemotherapeutic ap-
proach in second-line, we compared the outcome of pa-
tients receiving monotherapy with that of patients
treated with a combination regimen. No imbalances in
main patient characteristics (gender; age; performance
status; site of origin; disease stage; previous surgery; re-
sponse and PFS after first-line therapy; number of meta-
static sites; presence of bone, lung, liver or peritoneal
metastases; CA19.9 levels) between the two groups were
identified (all p > 0.05). A slight increase in disease con-
trol rate (DCR) (32 % vs. 21 %, p = 0.140) and PFS (me-
dian: 3.1 vs. 2.9 months; p = 0.072) (Fig. 1a) was
observed, but these differences did not reach statistical
significance. Of note, we reported prolonged OS with
combination chemotherapy compared to single-agent
(7.1 vs. 5.0 months; p = 0.006) (Fig. 1b).
At multivariate analysis, the following factors resulted
associated with prolonged PFS: ECOG performance sta-
tus of 0, lower CA19.9 pretreatment levels, absence of
lung involvement and male gender (Table 3). In terms of
OS, ECOG performance status of 0, CA19.9 levels below
the median value and locally advanced disease were
identified as positive prognostic determinants (Table 3).
When we adjusted the comparison between single-agent
and combination chemotherapy by performing a propen-
sity score analysis, the trend toward improved PFS with
multi-drug regimens was lost, while the significant ad-
vantage in terms of OS in favor of the combination was
actually more evident (Fig. 2).
Results of the pooled analysis
The results of this analysis have been grouped with those
of the other five trials identified [13–17], with a total of
499 patients (Table 4). All included series had data for
the analysis of PFS, while only five series (for a total of
462 patients) reported OS data and four series (for a
total of 420 patients) reported data on RR (Table 4).
Types of second-line chemotherapy used were the fol-
lowing: FOLFOX or XELOX or 5-fluorouracil plus cis-
platin in 128 patients, FOLFIRI in 75 patients (in 13 of
whom in combination with bevacizumab), 5-fluorouracil
or capecitabine monotherapy in 39 patients, gemcitabine
plus cisplatin in 17 patients and other regimens in 66
patients.
Overall RR with second-line chemotherapy was 10.2 %
(95 % CI 7.3 %-13.1 %). Median PFS and OS obtained by
a weighted pooled analysis of the available series were
3.1 (95 % CI: 2.9-3.4) and 6.3 (95 % CI 5.6-7.0) months,
respectively (Fig. 3).
Discussion
The GP combination has been recently set as the stand-
ard treatment for fit patients with aBTC [6, 7]. After
disease progression, no established alternatives are
available, and the potential benefit of second-line
Table 2 Retrospective cohort: second-line chemotherapy used
Chemotherapy regimen n. (%)
Monotherapy with 5-fluorouracil or capecitabine 49 (28)
Gemcitabine plus 5-fluorouracil or capecitabine 38 (22)
Capecitabine plus mytomicin-C 21 (12)
FOLFIRI or XELIRI 17 (10)
Retreatment with gemcitabine plus cisplatin or oxaliplatin 13 (7)
FOLFOX or XELOX 10 (6)
Epirubicin plus cisplatin plus 5-fluorouracil 9 (5)
Gemcitabine plus irinotecan 6 (3)
Monotherapy with gemcitabine 4 (2)
Other regimens 7 (4)
Abbreviations: n number, FOLFIRI 5-fluorouracil plus irinotecan, XELIRI capecitabine
plus irinotecan, FOLFOX 5-fluorouracil plus of oxaliplatin, XELOX capecitabine
plus oxaliplatin
Combination chemotherapy (n=118) 
Single-agent chemotherapy (n=56) 
p=0.072 
3.2% 
7.6% 
13.3% 
29.2% 
p=0.006 
Combination chemotherapy (n=118) 
Single-agent chemotherapy (n=56) 
A B 
Fig. 1 Outcome comparison between sing-agent and combination chemotherapy groups in the retrospective cohort: a) progression-free survival;
b) overall survival. Legend: PFS, progression-free survival; OS, overall survival
Fornaro et al. Journal of Experimental & Clinical Cancer Research  (2015) 34:156 Page 4 of 7
chemotherapy is currently under investigation in the
randomized phase III ABC-06 trial, comparing FOL-
FOX to active symptom control (ASC) [18]. Pre-
treated aBTC thus represents a challenging scenario
due to the paucity of reliable data about the useful-
ness of salvage chemotherapy.
The current analysis aims at refining the estimate of
activity and efficacy of second-line chemotherapy after a
standard GP combination in first-line. As in the general
population of pretreated aBTC [9], second-line chemo-
therapy after first-line GP confirms limited activity and
efficacy. We observed an overall RR of 10.2 %, with me-
dian PFS and OS of 3.1 and 6.3 months, respectively.
Available data thus indicate that only a minor percentage
of aBTC patients may achieve an objective response
after first disease progression with GP, with a limited
duration of disease control [9, 10]. These results con-
firm the need for a prospective evaluation of the efficacy
of second-line chemotherapy, in order to definitively
establish the relative benefit of medical treatment
over ASC alone.
Our analysis (and the already published studies in this
setting) does not allow establishing a preferable second-
line agent, as formal direct comparisons among the dif-
ferent regimens administered would suffer from several
limitations. However, we confirmed a trend toward im-
proved efficacy with second-line combination chemother-
apy compared with monotherapy, as already reported in
our previous report [10]. A propensity-score analysis was
conducted in order to reduce the influence of potential
confounding factors on the results: the survival difference
between single-agent and combination chemotherapy ac-
tually increased after adjustment, retaining statistical sig-
nificance. This observation may be of value as Lamarca et
al. found a correlation between RR or PFS and OS [9] and
at least partially supports the use of combination chemo-
therapy in pretreated aBTC. Outside of a clinical trial,
second-line fluoropyrimidine-based regimens (as tested in
the experimental arm of the ABC-06 study) could be thus
considered the most suitable option, with single-agent 5-
fluorouracil or capecitabine being reasonable alternatives
in unfit patients [10, 11, 19]. As mentioned, selection bias
as well as the limited number of patients after adjustment
for other factors may have influenced the results of our
analysis: of note, Brieau et al. [16] did not report signifi-
cant differences in terms of PFS and OS between mono-
therapy and combination chemotherapy and even in the
randomized Italian trial comparing second-line capecita-
bine with capecitabine plus mitomycin-C no additional
benefit was evident in favor of the multi-drug regimen [20].
Therefore, extreme caution is needed when trying to iden-
tify an optimal schedule in this setting.
As already described in a larger patient population
[10], some clinical and laboratory parameters may help
selecting optimal candidates for salvage chemotherapy.
We previously demonstrated that poor performance sta-
tus, elevated CA19.9 level, an on-site primary tumor and
Table 3 Multivariate prognostic factor analysis for PFS and OS
HR (95 % CI) p-value
Progression-free survival
ECOG PS, 1/2 vs. 0 1.94 (1.31-2.89) 0.001
CA19.9, ≥157 U/ml vs. <157 U/ml 1.58 (1.08-2.33) 0.019
Gender, female vs. male 1.49 (1.04-2.14) 0.028
Lung metastases, yes vs. no 1.48 (1.02-2.14) 0.040
Overall survival
ECOG PS, 1/2 vs. 0 3.56 (2.25-5.61) <0.001
Stage, metastatic vs. locally advanced 3.25 (1.58-6.69) 0.001
CA19.9, ≥157 U/ml vs. <157 U/ml 1.96 (1.25-3.05) 0.003
Abbreviations: ECOG PS Eastern Cooperative Oncology Group performance
status, HR hazard ratio; 95 % CI, 95 % confidence interval
8.5% 
38.6% 
p=0.008 
3.7% 
p=0.430 
Combination chemotherapy (n=49) 
Single-agent chemotherapy (n=49) 
Combination chemotherapy (n=49) 
Single-agent chemotherapy (n=49) 
A B 
Fig. 2 Outcome comparison adjusted for propensity score between sing-agent and combination chemotherapy groups in the retrospective
cohort: a) progression-free survival; b) overall survival. Legend: PFS, progression-free survival; OS, overall survival
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shorter first-line PFS negatively affect OS in second-line.
In the current retrospective series among GP-pretreated
patients, we confirmed the value of performance status
and CA19.9 as major determinants of prognosis at
multivariate analysis.
If the ABC-06 trial will clarify the role of second-line
chemotherapy, our analysis confirms that cytotoxic ther-
apy alone does not represent a definitive solution to the
aBTC problem. Up today, the role of biologic agents in
this setting is not established, and results in the first-
and second-line settings are limited [8]. The largely un-
known biological background behind biliary tumor pro-
gression represents one of the main limitations in the
development of targeted agents, reducing the chances of
an adequate molecular patient selection and tailored de-
velopment of newer agents [21]. As an example, cetuxi-
mab has been recently tested in combination with
gemcitabine plus oxaliplatin as first-line therapy among
aBTC patients stratified by KRAS status [22]: results of
the combination, however, remained disappointing even
in the KRAS wild-type subgroup. More intriguingly, in-
sights into BTC biology have recently led to the identifi-
cation of potential therapeutic targets [23–27]. Of note,
a recent paper has revealed that 9 % of the 65 evaluated
BTC cases showed ROS1 rearrangements at genetic ana-
lysis [23]: as in non-small cell lung cancer [28], this may
pave the way for the clinical evaluation of specific inhibi-
tors in aBTC patients.
Conclusions
To conclude, second-line chemotherapy confirmed lim-
ited efficacy after a first-line GP regimen in aBTC, both
in a large retrospective patient cohort and in a pooled
analysis of published and presented data. Prospective
Table 4 Studies included in the pooled analysis
Study [ref.] n. ECOG PS (n.) Basal CA19.9 (n.) median PFS
(95 % CI) (months)
median OS
(95 % CI) (months)
RR (%)
Present study 174 0: 1061: 522: 16 <157 U/ml: 71≥157 U/ml: 83NR: 20 3.0 (2.7-3.4) 6.6 (5.1-8.1) 3.4
He, 2014 [13] 37 0-1: 292: 8 normal: 9elevated: 28 3.1 (2.3-3.6) NR 21.6
Bridgewater, 2013 [14] 63 NR NR 4.0 (3.3-5.6) 8.1 (5.3-11.4) NR
Fiteni, 2014 [15] 16 NR NR 4.0 (2.6-5.5) 5.3 (4.1-6.6) NR
Brieau, 2015 [16] 196 0-1: 1172–3: 56 ≤400 U/ml: 81>400 U/ml: 49 3.2 (2.8-4.0) 6.7 (5.6-7.8) 11.8
Guion-Dusserre, 2015 [17] 13 0: 31: 82: 2 median: 73 U/ml [range: 2–4472] 8 (7–16) 20 (8–48) 38.4
Abbreviations: ref reference number, n number, ECOG PS Eastern Cooperative Oncology Group performance status, PFS progression-free survival, OS overall survival,
CI confidence interval, RR response, rate, NR not reported
Fig. 3 Pooled analysis of published data: a) progression-free survival; b) overall survival. Legend: Point estimates of progression-free survival and
overall survival times are expressed in months
Fornaro et al. Journal of Experimental & Clinical Cancer Research  (2015) 34:156 Page 6 of 7
trials such as ABC-06 are eagerly awaited to better de-
fine the role of salvage therapy compared with ASC: in
the meanwhile, a fluoropyrimidine and, in selected cases,
a fluoropyrimidine-based combination can be offered to
patients with a more favorable prognosis, as defined by
clinical and laboratory variables.
Abbreviations
aBTC: Advanced biliary tract cancer; BTC: Biliary tract cancer; GP: Gemcitabine
plus platinum derivative combination chemotherapy; OS: Overall survival;
PFS: Progression-free survival; RECIST: Response Evaluation Criteria in Solid
Tumors; RR: Response rate.
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